Dow Jones

39,871.51

0.00%

Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

Regístrate

ERAS

Erasca (ERAS)

Erasca Inc

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ERAS

1 2 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
17/05/2024	16:07	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:ERAS	Erasca Inc
17/05/2024	05:05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ERAS	Erasca Inc
16/05/2024	23:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:ERAS	Erasca Inc
15/05/2024	14:52	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ERAS	Erasca Inc
09/05/2024	15:18	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:ERAS	Erasca Inc
09/05/2024	15:14	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:ERAS	Erasca Inc
08/05/2024	15:12	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ERAS	Erasca Inc
13/02/2024	19:24	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:ERAS	Erasca Inc
07/02/2024	17:52	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ERAS	Erasca Inc
27/06/2023	15:07	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:ERAS	Erasca Inc
26/06/2023	15:07	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:ERAS	Erasca Inc
26/06/2023	08:13	Edgar (US Regulatory)	Amended Statement of Changes in Beneficial Ownership (4/a)	NASDAQ:ERAS	Erasca Inc
22/06/2023	15:56	Dow Jones News	Erasca's Eras-801 for Treatment of Brain Tumors Gets FDA Orphan Drug Designation	NASDAQ:ERAS	Erasca Inc
15/05/2023	16:22	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:ERAS	Erasca Inc
01/05/2023	05:10	Edgar (US Regulatory)	Annual Report to Security Holders (ars)	NASDAQ:ERAS	Erasca Inc
28/04/2023	15:28	Edgar (US Regulatory)	Proxy Statement (definitive) (def 14a)	NASDAQ:ERAS	Erasca Inc
23/03/2023	15:22	Edgar (US Regulatory)	Annual Report (10-k)	NASDAQ:ERAS	Erasca Inc
10/03/2023	08:31	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:ERAS	Erasca Inc
21/12/2022	15:33	Edgar (US Regulatory)	Amended Statement of Beneficial Ownership (sc 13d/a)	NASDAQ:ERAS	Erasca Inc
19/12/2022	15:22	Edgar (US Regulatory)	Statement of Ownership (sc 13g)	NASDAQ:ERAS	Erasca Inc
09/12/2022	16:23	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)	NASDAQ:ERAS	Erasca Inc
09/12/2022	12:15	Dow Jones News	Erasca Shares Drop 30% After Pricing of $100 Million Underwritten Offering, Novartis Agreement	NASDAQ:ERAS	Erasca Inc
09/12/2022	08:37	TipRanks	Erasca Slides After Public Offering; Inks Licensing Deal with NVS	NASDAQ:ERAS	Erasca Inc
11/08/2022	16:22	Edgar (US Regulatory)	Securities Registration Statement (simplified Form) (s-3)	NASDAQ:ERAS	Erasca Inc
13/05/2022	07:20	TipRanks	Erasca (ERAS) Receives a Buy from J.P. Morgan	NASDAQ:ERAS	Erasca Inc
28/04/2022	15:29	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	NASDAQ:ERAS	Erasca Inc
27/04/2022	16:53	Edgar (US Regulatory)	Initial Statement of Beneficial Ownership (3)	NASDAQ:ERAS	Erasca Inc
30/03/2022	07:06	TipRanks	Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Black Diamond Therapeutics (BDTX) and Erasca (ERAS)	NASDAQ:ERAS	Erasca Inc
08/09/2021	07:53	Dow Jones News	Erasca in Clinical Trial Collaboration Agreement With Pfizer	NASDAQ:ERAS	Erasca Inc
12/08/2021	09:39	Edgar (US Regulatory)	Sec Staff Action/letter (sec Staff)	NASDAQ:ERAS	Erasca Inc